Biophysical and biochemical insights in the design of immunoassays.

Infectious diseases Lateral flow immunoassay Nanoparticle-antibody conjugates Paperfluidic Protein-ligand affinity Rapid diagnostic Viral biomarkers

Journal

Biochimica et biophysica acta. General subjects
ISSN: 1872-8006
Titre abrégé: Biochim Biophys Acta Gen Subj
Pays: Netherlands
ID NLM: 101731726

Informations de publication

Date de publication:
01 2023
Historique:
received: 11 08 2022
revised: 17 10 2022
accepted: 21 10 2022
pubmed: 30 10 2022
medline: 18 11 2022
entrez: 29 10 2022
Statut: ppublish

Résumé

Rapid antigen assays have been attractive for decentralized, point of care diagnostics because of their low cost, robustness, and ease of use. The development of a diagnostic assay for a newly emerging infectious disease needs to take into account the progression of a disease, whether there is human to human transmission, and patient biomarker levels with time, and these all impact the choice of antigen targets and affinity agents. The factors involved in the biophysical design of rapid antigen immunoassays are discussed, focusing on antigen selection and designing for cross-reactivity. State of the art in the biophysical characterization of protein-ligand or antigen-antibody interactions, the different types of affinity agents used in immunoassays, and biochemical conjugation strategies are described. Antigen choice is a critical factor in immunoassay diagnostic development, and should account for the properties of the virion, virus, and disease progression. Biophysical and biochemical aspects of immunoassays are critical for performance. This review can serve as an instructive guide to aid in diagnostic development for future emerging diseases.

Sections du résumé

BACKGROUND
Rapid antigen assays have been attractive for decentralized, point of care diagnostics because of their low cost, robustness, and ease of use. The development of a diagnostic assay for a newly emerging infectious disease needs to take into account the progression of a disease, whether there is human to human transmission, and patient biomarker levels with time, and these all impact the choice of antigen targets and affinity agents.
SCOPE OF REVIEW
The factors involved in the biophysical design of rapid antigen immunoassays are discussed, focusing on antigen selection and designing for cross-reactivity. State of the art in the biophysical characterization of protein-ligand or antigen-antibody interactions, the different types of affinity agents used in immunoassays, and biochemical conjugation strategies are described.
MAJOR CONCLUSIONS
Antigen choice is a critical factor in immunoassay diagnostic development, and should account for the properties of the virion, virus, and disease progression. Biophysical and biochemical aspects of immunoassays are critical for performance.
GENERAL SIGNIFICANCE
This review can serve as an instructive guide to aid in diagnostic development for future emerging diseases.

Identifiants

pubmed: 36309294
pii: S0304-4165(22)00184-2
doi: 10.1016/j.bbagen.2022.130266
pii:
doi:

Substances chimiques

Proteins 0
Biomarkers 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

130266

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Josselyn Mata Calidonio (JM)

Dept. of Engineering, University of Massachusetts Boston, Boston, MA, USA.

Kimberly Hamad-Schifferli (K)

Dept. of Engineering, University of Massachusetts Boston, Boston, MA, USA; School for the Environment, University of Massachusetts Boston, Boston, MA, USA. Electronic address: kim.hamad@umb.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH